These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 27304060)
1. miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer. Kim YS; Park SJ; Lee YS; Kong HK; Park JH Oncotarget; 2016 Jul; 7(27):42261-42273. PubMed ID: 27304060 [TBL] [Abstract][Full Text] [Related]
2. MiRNA-500a-3p inhibits cell proliferation and invasion by targeting lymphocyte antigen 6 complex locus K (LY6K) in human non-small cell lung cancer. Liao XH; Xie Z; Guan CN Neoplasma; 2018 Sep; 65(5):673-682. PubMed ID: 30249107 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. Zhao JJ; Lin J; Yang H; Kong W; He L; Ma X; Coppola D; Cheng JQ J Biol Chem; 2008 Nov; 283(45):31079-86. PubMed ID: 18790736 [TBL] [Abstract][Full Text] [Related]
4. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer. Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890 [TBL] [Abstract][Full Text] [Related]
5. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143 [TBL] [Abstract][Full Text] [Related]
6. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer. Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377 [No Abstract] [Full Text] [Related]
7. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310 [TBL] [Abstract][Full Text] [Related]
9. Down-regulation of ZNF252P-AS1 alleviates ovarian cancer progression by binding miR-324-3p to downregulate LY6K. Geng L; Wang Z; Tian Y J Ovarian Res; 2022 Jan; 15(1):1. PubMed ID: 34980214 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. Martin EC; Conger AK; Yan TJ; Hoang VT; Miller DF; Buechlein A; Rusch DB; Nephew KP; Collins-Burow BM; Burow ME FEBS Lett; 2017 Jan; 591(2):382-392. PubMed ID: 28008602 [TBL] [Abstract][Full Text] [Related]
11. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959 [TBL] [Abstract][Full Text] [Related]
12. Loss of Estrogen-Regulated Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962 [TBL] [Abstract][Full Text] [Related]
13. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. Ergun S; Tayeb TS; Arslan A; Temiz E; Arman K; Safdar M; Dağlı H; Korkmaz M; Nacarkahya G; Kırkbeş S; Oztuzcu S Gene; 2015 Jan; 555(2):377-81. PubMed ID: 25447917 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803 [TBL] [Abstract][Full Text] [Related]
15. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells. Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927 [TBL] [Abstract][Full Text] [Related]
16. Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy. Zhu QN; Renaud H; Guo Y Hereditas; 2018; 155():17. PubMed ID: 29371858 [TBL] [Abstract][Full Text] [Related]
17. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Li J; Lu M; Jin J; Lu X; Xu T; Jin S Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449 [TBL] [Abstract][Full Text] [Related]
18. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines. Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600 [TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells. Jin ML; Kim YW; Jin HL; Kang H; Lee EK; Stallcup MR; Jeong KW Int J Cancer; 2018 Dec; 143(11):2871-2883. PubMed ID: 30191958 [TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]